Vânia Vilas-Boas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4692819/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Adverse Outcome Pathways as Versatile Tools in Liver Toxicity Testing. Methods in Molecular Biology, 2022, 2425, 521-535.	0.9	2
2	Nanosafety: An Evolving Concept to Bring the Safest Possible Nanomaterials to Society and Environment. Nanomaterials, 2022, 12, 1810.	4.1	9
3	Hepatotoxicity induced by nanomaterials: mechanisms and in vitro models. Archives of Toxicology, 2021, 95, 27-52.	4.2	23
4	Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. International Journal of Molecular Sciences, 2021, 22, 11005.	4.1	6
5	Cholestatic liver injury induced by food additives, dietary supplements and parenteral nutrition. Environment International, 2020, 136, 105422.	10.0	18
6	Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Archives of Toxicology, 2020, 94, 1151-1172.	4.2	28
7	Magnetic Hyperthermia for Cancer Treatment: Main Parameters Affecting the Outcome of In Vitro and In Vivo Studies. Molecules, 2020, 25, 2874.	3.8	63
8	Portable sensing system based on electrochemical impedance spectroscopy for the simultaneous quantification of free and total microcystin-LR in freshwaters. Biosensors and Bioelectronics, 2019, 142, 111550.	10.1	26
9	Increased Expression of Adherens Junction Components in Mouse Liver following Bile Duct Ligation. Biomolecules, 2019, 9, 636.	4.0	4
10	Effectiveness and Safety of a Nontargeted Boost for a CXCR4-Targeted Magnetic Hyperthermia Treatment of Cancer Cells. ACS Omega, 2019, 4, 1931-1940.	3.5	10
11	Industrial, Biocide, and Cosmetic Chemical Inducers of Cholestasis. Chemical Research in Toxicology, 2019, 32, 1327-1334.	3.3	16
12	Mechanisms and in vitro models of drug-induced cholestasis. Archives of Toxicology, 2019, 93, 1169-1186.	4.2	25
13	Biocompatibility and Bioimaging Potential of Fruit-Based Carbon Dots. Nanomaterials, 2019, 9, 199.	4.1	58
14	Primary hepatocytes and their cultures for the testing of drug-induced liver injury. Advances in Pharmacology, 2019, 85, 1-30.	2.0	13
15	Combining CXCR4-targeted and nontargeted nanoparticles for effective unassistedin vitromagnetic hyperthermia. Biointerphases, 2018, 13, 011005.	1.6	9
16	Green synthesis of fluorescent carbon dots from spices for in vitro imaging and tumour cell growth inhibition. Beilstein Journal of Nanotechnology, 2018, 9, 530-544.	2.8	139
17	Performance enhanced UV/vis spectroscopic microfluidic sensor for ascorbic acid quantification in human blood. Biosensors and Bioelectronics, 2016, 85, 568-572.	10.1	42
18	Induction and activation of P-glycoprotein efflux pump as a therapeutic strategy. Toxicology Letters, 2015, 238, S48.	0.8	0

VâNIA VILAS-BOAS

#	Article	IF	CITATIONS
19	Straightforward phase-transfer route to colloidal iron oxide nanoparticles for protein immobilization. RSC Advances, 2015, 5, 47954-47958.	3.6	6
20	Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. , 2015, 149, 1-123.		275
21	Several transport systems contribute to the intestinal uptake of Paraquat, modulating its cytotoxic effects. Toxicology Letters, 2015, 232, 271-283.	0.8	17
22	RBE4 cells are highly resistant to paraquatâ€induced cytotoxicity: studies on uptake and efflux mechanisms. Journal of Applied Toxicology, 2014, 34, 1023-1030.	2.8	19
23	The mixture of "ecstasy―and its metabolites is toxic to human SH-SY5Y differentiated cells at in vivo relevant concentrations. Archives of Toxicology, 2014, 88, 455-473.	4.2	45
24	Interaction of polyacrylic acid coated and non-coated iron oxide nanoparticles with human neutrophils. Toxicology Letters, 2014, 225, 57-65.	0.8	55
25	Colchicine effect on P-glycoprotein expression and activity: In silico and in vitro studies. Chemico-Biological Interactions, 2014, 218, 50-62.	4.0	33
26	Therapeutic Concentrations of Mitoxantrone Elicit Energetic Imbalance in H9c2 Cells as an Earlier Event. Cardiovascular Toxicology, 2013, 13, 413-425.	2.7	31
27	Doxorubicin decreases paraquat accumulation and toxicity in Caco-2 cells. Toxicology Letters, 2013, 217, 34-41.	0.8	23
28	Mechanisms of P-gp inhibition and effects on membrane fluidity of a new rifampicin derivative, 1,8-dibenzoyl-rifampicin. Toxicology Letters, 2013, 220, 259-266.	0.8	26
29	Development of Novel Rifampicin-Derived P-Glycoprotein Activators/Inducers. Synthesis, In Silico Analysis and Application in the RBE4 Cell Model, Using Paraquat as Substrate. PLoS ONE, 2013, 8, e74425.	2.5	23
30	Immortalized rat brain endothelial cells are highly resistant to paraquat toxic effect. Toxicology Letters, 2012, 211, S175.	0.8	0
31	Cocaine-induced kidney toxicity: an in vitro study using primary cultured human proximal tubular epithelial cells. Archives of Toxicology, 2012, 86, 249-261.	4.2	43
32	P-glycoprotein induction by hypericin protects Caco-2 cells against paraquat toxicity. Toxicology Letters, 2011, 205, S93-S94.	0.8	2
33	P-glycoprotein activity assessment in rat brain endothelial cells—A search for new rifampicin-derived p-glycoprotein inducers. Toxicology Letters, 2011, 205, S94-S95.	0.8	0
34	Pâ€glycoprotein activity in human Caucasian male lymphocytes does not follow its increased expression during aging. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2011, 79A, 912-919.	1.5	26